Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyErgocalciferol
Identification
- Name
- Ergocalciferol
- Accession Number
- DB00153 (NUTR00005, APRD00426)
- Type
- Small Molecule
- Groups
- Approved, Nutraceutical
- Description
Ergocalciferol (Vitamin D2) is a derivative of ergosterol formed by ultraviolet rays breaking of the C9-C10 bond. It differs from cholecalciferol in having a double bond between C22 and C23 and a methyl group at C24.
- Structure
Structure for DB00153 (Ergocalciferol)
- Synonyms
- (3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
- (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
- (5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
- Activated ergosterol
- Ercalciol
- Ergocalciférol
- Ergocalciferol
- Ergocalciferolum
- Oleovitamin D2
- Viosterol
- Vitamin D2
- Vitamina D2
- Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End D-forte Capsule 50000 unit Oral Euro Pharm International Canada Inc 2017-08-16 Not applicable Canada 
D-forte Capsule 50000 unit Oral Sandoz Canada Incorporated 1999-12-30 Not applicable Canada Drisdol Capsule, liquid filled 1.25 mg/1 Oral Avera Mc Kennan Hospital 2016-02-05 2018-07-07 US 
Drisdol Capsule, liquid filled 1.25 mg/1 Oral Validus Pharmaceuticals 2018-04-01 Not applicable US Drisdol Capsule, liquid filled 1.25 mg/1 Oral Sanofi Aventis 1974-11-11 2017-11-18 US Drisdol Capsule, liquid filled 1.25 mg/1 Oral Validus Pharmaceuticals 1974-01-11 2018-04-05 US M.V.I. Adult Kit Hospira, Inc. 2004-01-30 Not applicable US M.V.I. Adult Kit Hospira, Inc. 2004-01-30 2018-05-01 US Osto-D2 Capsule 50000 unit Oral Paladin Labs Inc 2008-02-08 Not applicable Canada Radiostol Cap 50000iu Capsule 50000 unit Oral Allen & Hanburys A Glaxo Canada Ltd. Co. 1989-12-15 1996-09-10 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Ergocalciferol Capsule, liquid filled 1.25 mg/1 Oral Ready Meds 2010-07-23 Not applicable US Ergocalciferol Capsule 1.25 mg/1 Oral Blenheim Pharmacal, Inc. 2013-10-02 Not applicable US Ergocalciferol Capsule, liquid filled 1.25 mg/1 Oral Av Kare, Inc. 2015-07-23 Not applicable US Ergocalciferol Capsule 1.25 mg/1 Oral A S Medication Solutions 2009-08-17 2017-06-20 US Ergocalciferol Capsule, liquid filled 1.25 mg/1 Oral Pd Rx Pharmaceuticals, Inc. 2016-06-15 Not applicable US Ergocalciferol Capsule 1.25 mg/1 Oral Aidarex Pharmaceuticals LLC 2009-08-17 Not applicable US Ergocalciferol Capsule 1.25 mg/1 Oral bryant ranch prepack 2009-08-17 Not applicable US Ergocalciferol Capsule, liquid filled 1.25 mg/1 Oral Banner Life Sciences Llc. 2015-06-01 Not applicable US Ergocalciferol Capsule 1.25 mg/1 Oral Aphena Pharma Solutions Tennessee, Inc. 2011-11-15 Not applicable US Ergocalciferol Capsule, liquid filled 1.25 mg/1 Oral Av Kare, Inc. 2012-06-05 2016-02-04 US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Aquasol A & D Drops Ergocalciferol (8000 unit) + Vitamin A (40000 unit) Solution / drops Oral Rhone Poulenc Rorer 1993-12-31 1996-09-09 Canada Cal/mag 2:1 With D Ergocalciferol (100 unit) + Calcium (350 mg) + Magnesium cation (175 mg) Tablet Oral Wn Pharmaceuticals Ltd. 1998-06-26 2000-02-02 Canada Calcium Mg and Zn Capsules With Vitamin D Ergocalciferol (100 unit) + Calcium (333.33 mg) + Magnesium cation (166.67 mg) + Zinc (6 mg) Capsule Oral Rheingold Food International Ltd. 1995-12-31 2007-07-26 Canada Calcium Chelate Plus Vit D Ergocalciferol (400 unit) + Calcium (50 mg) Tablet Oral Hall Laboratories, Ltd. 1981-12-31 2003-09-11 Canada Calcium Citrate W Vitamin D Tab Ergocalciferol (100 unit) + Calcium Citrate (250 mg) Tablet Oral Nutri Dyn Products Ltd. 1994-12-31 1996-09-09 Canada Calcium Magnesium 2:1 Tablets With Vitamin D Ergocalciferol (200 unit) + Calcium (300 mg) + Magnesium cation (150 mg) Tablet Oral Sisu Inc. 2004-01-30 2009-08-04 Canada Calcium Magnesium Avec Vitamine D Et Zinc Ergocalciferol (135 unit) + Calcium (335 mg) + Magnesium oxide (167 mg) + Zinc gluconate (10 mg) Tablet Oral Les Aliments Nutri Source Inc. 1991-12-31 1996-09-09 Canada Calcium Magnesium Plus Vitamin D Liquid Ergocalciferol (2 unit) + Calcium gluconate (6 mg) + Inositol nicotinate (.6 mg) + Magnesium citrate (3 mg) Liquid Oral Jamp Pharma Corporation 2002-04-22 2003-02-05 Canada Calcium With Vitamin D2 Ergocalciferol (200 unit) + Calcium (250 mg) Capsule Oral Sisu Inc. 2002-12-18 2008-07-25 Canada Calcium With Vitamins C and D Tab Ergocalciferol (200 unit) + Ascorbic acid (10 mg) + Calcium (500 mg) Tablet Oral Pure Life International Prods Inc. 1993-12-31 2000-07-27 Canada - International/Other Brands
- Calcidol / Deltalin
- Categories
- Alimentary Tract and Metabolism
- Bone Density Conservation Agents
- Cholestanes
- Cholestenes
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A4 Substrates (strength unknown)
- Diet, Food, and Nutrition
- Food
- Food and Beverages
- Growth Substances
- Lipids
- Membrane Lipids
- Micronutrients
- Physiological Phenomena
- Secosteroids
- Steroids
- Sterols
- Vitamin D and Analogues
- Vitamins
- UNII
- VS041H42XC
- CAS number
- 50-14-6
- Weight
- Average: 396.6484
Monoisotopic: 396.33921603 - Chemical Formula
- C28H44O
- InChI Key
- MECHNRXZTMCUDQ-RKHKHRCZSA-N
- InChI
- InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1
- IUPAC Name
- (1S,3Z)-3-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol
- SMILES
- CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
Pharmacology
- Indication
For use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of nutritional rickets or osteomalacia, vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).
- Associated Conditions
- Associated Therapies
- Pharmacodynamics
Ergoalcifediol (Vitamin D2) is a fat soluble steroid hormone precursor of vitamin D. The principal biologic function of vitamin D is the maintenance of normal levels of serum calcium and phosphorus in the bloodstream by enhancing the efficacy of the small intestine to absorb these minerals from the diet. Cholecalciferol is synthesized within our bodies naturally, but if UV exposure is inadequate or the metabolism of cholecalciferol is abnormal, then an exogenous source is required. Vitamin D2 is converted to 25-hydroxyvitamin D (25OHD) in the liver, and then to the active form, 1,25-dihydroxyvitamin D (1,25(OH)2D), in the kidney. Once transformed, it binds to the vitamin D receptor, which leads to a variety of regulatory roles. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma. Very few foods naturally contain vitamin D. Sources that contain the vitamin include fatty fish, the liver and fat of aquatic mammals (e.g., seals, polar bears), and eggs from chickens fed vitamin D-fortified feed. As such, many countries have instituted policies to fortify certain foods with vitamin D to compensate for the potentially low exposures of skin to sunlight. Vitamin D deficiency results in inadequate mineralization of bone or compensatory skeletal demineralization and causes decreased ionized calcium concentrations in blood and a resultant increase in the production and secretion of PTH. Increase in PTH stimulates the mobilization of skeletal calcium, inhibits renal excretion of calcium, and stimulates renal excretion of phosphorus. This results in normal fasting serum calcium concentrations and low or near-normal serum phosphorus. The enhanced mobilization of skeletal calcium induced by this secondary hyperparathyroidism leads porotic bone.
- Mechanism of action
Activated ergocalciferol increases serum calcium and phosphate concentrations, primarily by increasing intestinal absorption of calcium and phosphate through binding to a specific receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein. 25-hydroxyergocalciferol is the intermediary metabolite of ergocalciferol. Although this metabolite exhibits 2–5 times more activity than unactivated ergocalciferol in curing rickets and inducing calcium absorption and mobilization (from bone) in animals, this increased activity is still insufficient to affect these functions at physiologic concentrations. Activated ergocalciferol stimulate resorption of bone and are required for normal mineralization of bone. Physiological doses of ergocalciferol also promotes calcium reabsorption by the kidneys, but the significance of this effect is not known.
Target Actions Organism AVitamin D3 receptor agonistHuman - Absorption
Readily absorbed from small intestine (proximal or distal), requires presence of bile salts.
- Volume of distribution
- Not Available
- Protein binding
>99.8%
- Metabolism
Within the liver, ergocalciferol is hydroxylated to ercalcidiol (25-hydroxyergocalciferol) by the enzyme 25-hydroxylase. Within the kidney, ercalcidiol serves as a substrate for 1-alpha-hydroxylase, yielding ercalcitriol (1,25-dihydroxyergocalciferol), the biologically active form of vitamin D2.
- Route of elimination
- Not Available
- Half life
19 to 48 hours (however, stored in fat deposits in body for prolonged periods).
- Clearance
- Not Available
- Toxicity
LD50 = 23.7 mg/kg (Orally in mice); LD50 = 10 mg/kg (Orally in rats ); Nausea, vomiting and diarrhea, weight loss, irritability, weakness, fatigue, lassitude, and headache.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Acetyl sulfisoxazole The metabolism of Ergocalciferol can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Acetyldigitoxin Ergocalciferol may increase the arrhythmogenic activities of Acetyldigitoxin. Approved Acetyldigoxin Ergocalciferol may increase the arrhythmogenic activities of Acetyldigoxin. Experimental Alfacalcidol The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Alfacalcidol. Approved, Nutraceutical Aluminum hydroxide The serum concentration of Aluminum hydroxide can be increased when it is combined with Ergocalciferol. Approved, Investigational Amiodarone The metabolism of Ergocalciferol can be decreased when combined with Amiodarone. Approved, Investigational Apalutamide The serum concentration of Ergocalciferol can be decreased when it is combined with Apalutamide. Approved, Investigational Aprepitant The serum concentration of Ergocalciferol can be increased when it is combined with Aprepitant. Approved, Investigational Atazanavir The metabolism of Ergocalciferol can be decreased when combined with Atazanavir. Approved, Investigational Atomoxetine The metabolism of Ergocalciferol can be decreased when combined with Atomoxetine. Approved Beclomethasone dipropionate The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Beclomethasone dipropionate. Approved, Investigational Bendroflumethiazide The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Bendroflumethiazide. Approved Benzthiazide The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Benzthiazide. Approved Boceprevir The metabolism of Ergocalciferol can be decreased when combined with Boceprevir. Approved, Withdrawn Bortezomib The metabolism of Ergocalciferol can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Ergocalciferol can be decreased when it is combined with Bosentan. Approved, Investigational Budesonide The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Budesonide. Approved Calcidiol The risk or severity of adverse effects can be increased when Calcidiol is combined with Ergocalciferol. Approved, Nutraceutical Calcipotriol The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Calcipotriol. Approved Calcitriol The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Calcitriol. Approved, Nutraceutical Calcium Acetate The risk or severity of adverse effects can be increased when Calcium Acetate is combined with Ergocalciferol. Approved, Investigational Calcium Carbonate The risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Ergocalciferol. Approved, Investigational Calcium Chloride The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Ergocalciferol. Approved Calcium Citrate The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Ergocalciferol. Approved Calcium glubionate The risk or severity of adverse effects can be increased when Calcium glubionate is combined with Ergocalciferol. Approved Calcium Gluceptate The risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Ergocalciferol. Approved Calcium gluconate The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Ergocalciferol. Approved, Vet Approved Calcium lactate The risk or severity of adverse effects can be increased when Calcium lactate is combined with Ergocalciferol. Approved, Investigational, Vet Approved Calcium lactate gluconate The risk or severity of adverse effects can be increased when Calcium lactate gluconate is combined with Ergocalciferol. Experimental Calcium levulinate The risk or severity of adverse effects can be increased when Calcium levulinate is combined with Ergocalciferol. Approved, Experimental Calcium pangamate The risk or severity of adverse effects can be increased when Calcium pangamate is combined with Ergocalciferol. Experimental Calcium Phosphate The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Ergocalciferol. Approved Carbamazepine The metabolism of Ergocalciferol can be increased when combined with Carbamazepine. Approved, Investigational Casein The risk or severity of adverse effects can be increased when Casein is combined with Ergocalciferol. Approved Ceritinib The serum concentration of Ergocalciferol can be increased when it is combined with Ceritinib. Approved Chlorothiazide The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Chlorothiazide. Approved, Vet Approved Chlorthalidone The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Chlorthalidone. Approved Cholecalciferol The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Cholecalciferol. Approved, Nutraceutical Cholestyramine The serum concentration of Ergocalciferol can be decreased when it is combined with Cholestyramine. Approved, Investigational Clarithromycin The metabolism of Ergocalciferol can be decreased when combined with Clarithromycin. Approved Clotrimazole The metabolism of Ergocalciferol can be decreased when combined with Clotrimazole. Approved, Vet Approved Cobicistat The metabolism of Ergocalciferol can be decreased when combined with Cobicistat. Approved Colesevelam The serum concentration of Ergocalciferol can be decreased when it is combined with Colesevelam. Approved Colestipol The serum concentration of Ergocalciferol can be decreased when it is combined with Colestipol. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Ergocalciferol. Approved, Investigational Crizotinib The metabolism of Ergocalciferol can be decreased when combined with Crizotinib. Approved Curcumin The metabolism of Ergocalciferol can be decreased when combined with Curcumin. Approved, Investigational Cyclopenthiazide The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Cyclopenthiazide. Experimental Cyclosporine The metabolism of Ergocalciferol can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cymarin Ergocalciferol may increase the arrhythmogenic activities of Cymarin. Experimental Dabrafenib The serum concentration of Ergocalciferol can be decreased when it is combined with Dabrafenib. Approved, Investigational Danazol Danazol may increase the hypercalcemic activities of Ergocalciferol. Approved Darunavir The metabolism of Ergocalciferol can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Ergocalciferol can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Ergocalciferol can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Ergocalciferol can be decreased when combined with Delavirdine. Approved Deslanoside Ergocalciferol may increase the arrhythmogenic activities of Deslanoside. Approved Dexamethasone The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Dexamethasone. Approved, Investigational, Vet Approved Digitoxin Ergocalciferol may increase the arrhythmogenic activities of Digitoxin. Approved, Investigational Digoxin Ergocalciferol may increase the arrhythmogenic activities of Digoxin. Approved Digoxin Immune Fab (Ovine) Ergocalciferol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine). Approved Dihydroergotamine The metabolism of Ergocalciferol can be decreased when combined with Dihydroergotamine. Approved, Investigational Dihydrotachysterol The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Dihydrotachysterol. Approved Diltiazem The metabolism of Ergocalciferol can be decreased when combined with Diltiazem. Approved, Investigational Doxercalciferol The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Ergocalciferol. Approved Doxycycline The metabolism of Ergocalciferol can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone The metabolism of Ergocalciferol can be decreased when combined with Dronedarone. Approved Enzalutamide The serum concentration of Ergocalciferol can be decreased when it is combined with Enzalutamide. Approved Epitizide The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Epitizide. Experimental Erythromycin The metabolism of Ergocalciferol can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Fluconazole The metabolism of Ergocalciferol can be decreased when combined with Fluconazole. Approved, Investigational Fluticasone propionate The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Fluticasone propionate. Approved Fluvoxamine The metabolism of Ergocalciferol can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Ergocalciferol can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Ergocalciferol can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The metabolism of Ergocalciferol can be increased when combined with Fosphenytoin. Approved, Investigational Fusidic Acid The serum concentration of Ergocalciferol can be increased when it is combined with Fusidic Acid. Approved, Investigational Gitoformate Ergocalciferol may increase the arrhythmogenic activities of Gitoformate. Experimental Hydrochlorothiazide The risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Ergocalciferol. Approved, Vet Approved Hydrocortisone The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Hydrocortisone. Approved, Vet Approved Hydrocortisone acetate The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Hydrocortisone acetate. Approved, Vet Approved Hydrocortisone butyrate The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Hydrocortisone butyrate. Approved, Vet Approved Hydroflumethiazide The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Hydroflumethiazide. Approved, Investigational Idelalisib The metabolism of Ergocalciferol can be decreased when combined with Idelalisib. Approved Imatinib The metabolism of Ergocalciferol can be decreased when combined with Imatinib. Approved Indapamide The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Indapamide. Approved Indinavir The metabolism of Ergocalciferol can be decreased when combined with Indinavir. Approved Isavuconazole The serum concentration of Ergocalciferol can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Ergocalciferol can be decreased when combined with Isavuconazonium. Approved, Investigational Itraconazole The metabolism of Ergocalciferol can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Ergocalciferol can be increased when it is combined with Ivacaftor. Approved Ketoconazole The metabolism of Ergocalciferol can be decreased when combined with Ketoconazole. Approved, Investigational Lanatoside C Ergocalciferol may increase the arrhythmogenic activities of Lanatoside C. Experimental Lopinavir The metabolism of Ergocalciferol can be decreased when combined with Lopinavir. Approved Lorpiprazole The serum concentration of Ergocalciferol can be increased when it is combined with Lorpiprazole. Approved Lovastatin The metabolism of Ergocalciferol can be decreased when combined with Lovastatin. Approved, Investigational Luliconazole The serum concentration of Ergocalciferol can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Ergocalciferol can be increased when combined with Lumacaftor. Approved Methyclothiazide The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Methyclothiazide. Approved Methylprednisolone The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Methylprednisolone. Approved, Vet Approved Metildigoxin Ergocalciferol may increase the arrhythmogenic activities of Metildigoxin. Experimental Metolazone The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Metolazone. Approved Mibefradil The metabolism of Ergocalciferol can be decreased when combined with Mibefradil. Investigational, Withdrawn Miconazole The metabolism of Ergocalciferol can be decreased when combined with Miconazole. Approved, Investigational, Vet Approved Mifepristone The serum concentration of Ergocalciferol can be increased when it is combined with Mifepristone. Approved, Investigational Mineral oil Mineral oil can cause a decrease in the absorption of Ergocalciferol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Mitotane The serum concentration of Ergocalciferol can be decreased when it is combined with Mitotane. Approved Nefazodone The metabolism of Ergocalciferol can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Ergocalciferol can be decreased when combined with Nelfinavir. Approved Netupitant The serum concentration of Ergocalciferol can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Ergocalciferol can be increased when combined with Nevirapine. Approved Nicardipine The metabolism of Ergocalciferol can be decreased when combined with Nicardipine. Approved, Investigational Nilotinib The metabolism of Ergocalciferol can be decreased when combined with Nilotinib. Approved, Investigational Olaparib The metabolism of Ergocalciferol can be decreased when combined with Olaparib. Approved Oleandrin Ergocalciferol may increase the arrhythmogenic activities of Oleandrin. Experimental, Investigational Orlistat The serum concentration of Ergocalciferol can be decreased when it is combined with Orlistat. Approved, Investigational Osimertinib The serum concentration of Ergocalciferol can be increased when it is combined with Osimertinib. Approved Ouabain Ergocalciferol may increase the arrhythmogenic activities of Ouabain. Approved Palbociclib The serum concentration of Ergocalciferol can be increased when it is combined with Palbociclib. Approved, Investigational Paricalcitol The risk or severity of adverse effects can be increased when Paricalcitol is combined with Ergocalciferol. Approved, Investigational Pentobarbital The metabolism of Ergocalciferol can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Peruvoside Ergocalciferol may increase the arrhythmogenic activities of Peruvoside. Experimental Phenobarbital The metabolism of Ergocalciferol can be increased when combined with Phenobarbital. Approved, Investigational Phenytoin The metabolism of Ergocalciferol can be increased when combined with Phenytoin. Approved, Vet Approved Pitolisant The serum concentration of Ergocalciferol can be decreased when it is combined with Pitolisant. Approved, Investigational Polythiazide The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Polythiazide. Approved Posaconazole The metabolism of Ergocalciferol can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Prednisolone The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Prednisolone. Approved, Vet Approved Primidone The metabolism of Ergocalciferol can be increased when combined with Primidone. Approved, Vet Approved Proscillaridin Ergocalciferol may increase the arrhythmogenic activities of Proscillaridin. Experimental Quinethazone The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Quinethazone. Approved Ranolazine The metabolism of Ergocalciferol can be decreased when combined with Ranolazine. Approved, Investigational Rifabutin The metabolism of Ergocalciferol can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Ergocalciferol can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Ergocalciferol can be increased when combined with Rifapentine. Approved, Investigational Rucaparib The metabolism of Ergocalciferol can be decreased when combined with Rucaparib. Approved, Investigational Saquinavir The metabolism of Ergocalciferol can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Sarilumab. Approved, Investigational Sildenafil The metabolism of Ergocalciferol can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Ergocalciferol can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Ergocalciferol can be increased when it is combined with Simeprevir. Approved St. John's Wort The serum concentration of Ergocalciferol can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Ergocalciferol can be increased when it is combined with Stiripentol. Approved Sucralfate The serum concentration of Sucralfate can be increased when it is combined with Ergocalciferol. Approved Sulfisoxazole The metabolism of Ergocalciferol can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Telaprevir The metabolism of Ergocalciferol can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Ergocalciferol can be decreased when combined with Telithromycin. Approved Ticlopidine The metabolism of Ergocalciferol can be decreased when combined with Ticlopidine. Approved Tocilizumab The serum concentration of Ergocalciferol can be decreased when it is combined with Tocilizumab. Approved Trichlormethiazide The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Trichlormethiazide. Approved, Vet Approved Vemurafenib The serum concentration of Ergocalciferol can be decreased when it is combined with Vemurafenib. Approved Verapamil The metabolism of Ergocalciferol can be decreased when combined with Verapamil. Approved Voriconazole The metabolism of Ergocalciferol can be decreased when combined with Voriconazole. Approved, Investigational Ziprasidone The metabolism of Ergocalciferol can be decreased when combined with Ziprasidone. Approved - Food Interactions
- Not Available
References
- Synthesis Reference
Charles W. Bishop, Glenville Jones, Ronald L. Horst, Nicholas J. Koszewski, Joyce C. Knutson, Raju Penmasta, Robert M. Moriarty, Stephen Strugnell, Timothy A. Reinhardt, Liang Guo, Sanjay K. Singhal, Lei Zhao, "Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2." U.S. Patent US5789397, issued March, 1992.
US5789397- General References
- DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S. [PubMed:15585789]
- External Links
- Human Metabolome Database
- HMDB0000900
- KEGG Drug
- D00187
- KEGG Compound
- C05441
- PubChem Compound
- 5280793
- PubChem Substance
- 46505053
- ChemSpider
- 4444351
- ChEBI
- 28934
- ChEMBL
- CHEMBL1536
- Therapeutic Targets Database
- DAP000291
- PharmGKB
- PA449484
- HET
- D2V
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Ergocalciferol
- ATC Codes
- A11CC01 — Ergocalciferol
- AHFS Codes
- 88:16.00 — Vitamin D
- PDB Entries
- 3czh
- MSDS
- Download (78.4 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Eli lilly and co
- Sanofi aventis us llc
- Orit laboratories llc
- Sigmapharm laboratories llc
- Strides arcolab ltd
- Sun pharmaceutical industries inc
- Banner pharmacaps inc
- Chase chemical co lp
- Everylife
- Impax laboratories inc
- Lannett co inc
- Vitarine pharmaceuticals inc
- West ward pharmaceutical corp
- Packagers
- Banner Pharmacaps Inc.
- Bayer Healthcare
- Breckenridge Pharmaceuticals
- Caraco Pharmaceutical Labs
- Gallipot
- Longs Drug Store
- Major Pharmaceuticals
- Optimum Pharmacueticals Inc.
- PD-Rx Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Pliva Inc.
- Rising Pharmaceuticals
- Sanofi-Aventis Inc.
- Superior Pharmeceuticals
- Walgreen Co.
- Winthrop Us
- Dosage forms
Form Route Strength Solution / drops Oral Capsule Oral Tablet Oral Capsule Oral 1.25 mg/1 Capsule, liquid filled Oral 1.25 mg/1 Tablet, effervescent Oral Kit Injection, solution, concentrate Intravenous Liquid Intravenous Syrup Oral Capsule Oral 50000 unit Capsule Oral 1.25 1/1 Liquid Oral - Prices
Unit description Cost Unit Ergocalciferol powder 234.4USD g Doral 15 mg tablet 3.41USD tablet Doral 7.5 mg tablet 3.37USD tablet Drisdol 50000 unit capsule 2.34USD capsule Drisdol 8288 unit/ml Liquid 0.48USD ml Vitamin d 400 unit softgel 0.04USD softgel capsule Longs vitamin d 400 unit tablet 0.03USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 116.5 °C PhysProp water solubility 50 mg/L TOMLIN,C (1994) logP 7.3 Not Available - Predicted Properties
Property Value Source Water Solubility 0.000433 mg/mL ALOGPS logP 7.59 ALOGPS logP 7.05 ChemAxon logS -6 ALOGPS pKa (Strongest Acidic) 18.38 ChemAxon pKa (Strongest Basic) -1.3 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 1 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 20.23 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 128.89 m3·mol-1 ChemAxon Polarizability 50.73 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9428 Caco-2 permeable + 0.8323 P-glycoprotein substrate Substrate 0.6628 P-glycoprotein inhibitor I Inhibitor 0.7614 P-glycoprotein inhibitor II Non-inhibitor 0.8391 Renal organic cation transporter Non-inhibitor 0.796 CYP450 2C9 substrate Non-substrate 0.8432 CYP450 2D6 substrate Non-substrate 0.9003 CYP450 3A4 substrate Substrate 0.7362 CYP450 1A2 substrate Non-inhibitor 0.9046 CYP450 2C9 inhibitor Non-inhibitor 0.8924 CYP450 2D6 inhibitor Non-inhibitor 0.9519 CYP450 2C19 inhibitor Non-inhibitor 0.8784 CYP450 3A4 inhibitor Non-inhibitor 0.8142 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8163 Ames test Non AMES toxic 0.9401 Carcinogenicity Non-carcinogens 0.9169 Biodegradation Not ready biodegradable 0.9742 Rat acute toxicity 3.6931 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8502 hERG inhibition (predictor II) Non-inhibitor 0.7513
Spectra
- Mass Spec (NIST)
- Download (9.78 KB)
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Vitamin D and derivatives
- Direct Parent
- Vitamin D and derivatives
- Alternative Parents
- Triterpenoids / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives
- Substituents
- Triterpenoid / Cyclic alcohol / Secondary alcohol / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Alcohol / Aliphatic homopolycyclic compound
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- hydroxy seco-steroid, seco-ergostane, vitamin D (CHEBI:28934) / Vitamin D2 and derivatives, Fat-soluble vitamins (C05441) / Vitamin D2 and derivatives (LMST03010000)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B...
- Gene Name
- VDR
- Uniprot ID
- P11473
- Uniprot Name
- Vitamin D3 receptor
- Molecular Weight
- 48288.64 Da
References
- Carvallo L, Henriquez B, Olate J, van Wijnen AJ, Lian JB, Stein GS, Onate S, Stein JL, Montecino M: The 1alpha,25-dihydroxy Vitamin D3 receptor preferentially recruits the coactivator SRC-1 during up-regulation of the osteocalcin gene. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):420-4. Epub 2007 Jan 10. [PubMed:17218095]
- Liu W, Tretiakova M, Kong J, Turkyilmaz M, Li YC, Krausz T: Expression of vitamin D3 receptor in kidney tumors. Hum Pathol. 2006 Oct;37(10):1268-78. Epub 2006 Jul 27. [PubMed:16949927]
- Ewing AK, Attner M, Chakravarti D: Novel regulatory role for human Acf1 in transcriptional repression of vitamin D3 receptor-regulated genes. Mol Endocrinol. 2007 Aug;21(8):1791-806. Epub 2007 May 22. [PubMed:17519354]
- Gallagher JC, Sai AJ: Vitamin D insufficiency, deficiency, and bone health. J Clin Endocrinol Metab. 2010 Jun;95(6):2630-3. doi: 10.1210/jc.2010-0918. [PubMed:20525913]
- Straube S, Derry S, Moore RA, McQuay HJ: Vitamin D for the treatment of chronic painful conditions in adults. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007771. doi: 10.1002/14651858.CD007771.pub2. [PubMed:20091647]
- Jurutka PW, Bartik L, Whitfield GK, Mathern DR, Barthel TK, Gurevich M, Hsieh JC, Kaczmarska M, Haussler CA, Haussler MR: Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J Bone Miner Res. 2007 Dec;22 Suppl 2:V2-10. doi: 10.1359/jbmr.07s216. [PubMed:18290715]
- Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E: Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate. 2007 Jun 15;67(9):911-23. [PubMed:17440943]
- Marks HD, Fleet JC, Peleg S: Transgenic expression of the human Vitamin D receptor (hVDR) in the duodenum of VDR-null mice attenuates the age-dependent decline in calcium absorption. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):513-6. Epub 2007 Jan 5. [PubMed:17207992]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxidoreductase activity
- Specific Function
- Has a role in maintaining calcium homeostasis. Catalyzes the NADPH-dependent 24-hydroxylation of calcidiol (25-hydroxyvitamin D(3)) and calcitriol (1-alpha,25-dihydroxyvitamin D(3)). The enzyme can...
- Gene Name
- CYP24A1
- Uniprot ID
- Q07973
- Uniprot Name
- 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial
- Molecular Weight
- 58874.695 Da
References
- Masuda S, Strugnell SA, Knutson JC, St-Arnaud R, Jones G: Evidence for the activation of 1alpha-hydroxyvitamin D2 by 25-hydroxyvitamin D-24-hydroxylase: delineation of pathways involving 1alpha,24-dihydroxyvitamin D2 and 1alpha,25-dihydroxyvitamin D2. Biochim Biophys Acta. 2006 Feb;1761(2):221-34. Epub 2006 Feb 2. [PubMed:16516540]
- Sakaki T, Kagawa N, Yamamoto K, Inouye K: Metabolism of vitamin D3 by cytochromes P450. Front Biosci. 2005 Jan 1;10:119-34. Print 2005 Jan 1. [PubMed:15574355]
- Abe D, Sakaki T, Kusudo T, Kittaka A, Saito N, Suhara Y, Fujishima T, Takayama H, Hamamoto H, Kamakura M, Ohta M, Inouye K: Metabolism of 2 alpha-propoxy-1 alpha,25-dihydroxyvitamin D3 and 2 alpha-(3-hydroxypropoxy)-1 alpha,25-dihydroxyvitamin D3 by human CYP27A1 and CYP24A1. Drug Metab Dispos. 2005 Jun;33(6):778-84. Epub 2005 Mar 11. [PubMed:15764712]
- Sakaki T: [Recent studies on vitamin D metabolizing enzymes]. Clin Calcium. 2006 Jul;16(7):1129-35. [PubMed:16816472]
- Inouye K, Sakaki T: Enzymatic studies on the key enzymes of vitamin D metabolism; 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24). Biotechnol Annu Rev. 2001;7:179-94. [PubMed:11686044]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Iron ion binding
- Specific Function
- Catalyzes the conversion of 25-hydroxyvitamin D3 (25(OH)D) to 1-alpha,25-dihydroxyvitamin D3 (1,25(OH)2D) plays an important role in normal bone growth, calcium metabolism, and tissue differentiation.
- Gene Name
- CYP27B1
- Uniprot ID
- O15528
- Uniprot Name
- 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial
- Molecular Weight
- 56503.475 Da
References
- Turunen MM, Dunlop TW, Carlberg C, Vaisanen S: Selective use of multiple vitamin D response elements underlies the 1 alpha,25-dihydroxyvitamin D3-mediated negative regulation of the human CYP27B1 gene. Nucleic Acids Res. 2007;35(8):2734-47. Epub 2007 Apr 10. [PubMed:17426122]
- Gallagher JC, Sai AJ: Vitamin D insufficiency, deficiency, and bone health. J Clin Endocrinol Metab. 2010 Jun;95(6):2630-3. doi: 10.1210/jc.2010-0918. [PubMed:20525913]
- Sakaki T, Kagawa N, Yamamoto K, Inouye K: Metabolism of vitamin D3 by cytochromes P450. Front Biosci. 2005 Jan 1;10:119-34. Print 2005 Jan 1. [PubMed:15574355]
- Sakaki T: [Recent studies on vitamin D metabolizing enzymes]. Clin Calcium. 2006 Jul;16(7):1129-35. [PubMed:16816472]
- Inouye K, Sakaki T: Enzymatic studies on the key enzymes of vitamin D metabolism; 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24). Biotechnol Annu Rev. 2001;7:179-94. [PubMed:11686044]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Catalyzes the first step in the oxidation of the side chain of sterol intermediates; the 27-hydroxylation of 5-beta-cholestane-3-alpha,7-alpha,12-alpha-triol. Has also a vitamin D3-25-hydroxylase a...
- Gene Name
- CYP27A1
- Uniprot ID
- Q02318
- Uniprot Name
- Sterol 26-hydroxylase, mitochondrial
- Molecular Weight
- 60234.28 Da
References
- Binkley N, Ramamurthy R, Krueger D: Low vitamin D status: definition, prevalence, consequences, and correction. Endocrinol Metab Clin North Am. 2010 Jun;39(2):287-301, table of contents. doi: 10.1016/j.ecl.2010.02.008. [PubMed:20511052]
- Masuda S, Strugnell SA, Knutson JC, St-Arnaud R, Jones G: Evidence for the activation of 1alpha-hydroxyvitamin D2 by 25-hydroxyvitamin D-24-hydroxylase: delineation of pathways involving 1alpha,24-dihydroxyvitamin D2 and 1alpha,25-dihydroxyvitamin D2. Biochim Biophys Acta. 2006 Feb;1761(2):221-34. Epub 2006 Feb 2. [PubMed:16516540]
- Sakaki T, Kagawa N, Yamamoto K, Inouye K: Metabolism of vitamin D3 by cytochromes P450. Front Biosci. 2005 Jan 1;10:119-34. Print 2005 Jan 1. [PubMed:15574355]
- Abe D, Sakaki T, Kusudo T, Kittaka A, Saito N, Suhara Y, Fujishima T, Takayama H, Hamamoto H, Kamakura M, Ohta M, Inouye K: Metabolism of 2 alpha-propoxy-1 alpha,25-dihydroxyvitamin D3 and 2 alpha-(3-hydroxypropoxy)-1 alpha,25-dihydroxyvitamin D3 by human CYP27A1 and CYP24A1. Drug Metab Dispos. 2005 Jun;33(6):778-84. Epub 2005 Mar 11. [PubMed:15764712]
- Sakaki T: [Recent studies on vitamin D metabolizing enzymes]. Clin Calcium. 2006 Jul;16(7):1129-35. [PubMed:16816472]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Binkley N, Ramamurthy R, Krueger D: Low vitamin D status: definition, prevalence, consequences, and correction. Endocrinol Metab Clin North Am. 2010 Jun;39(2):287-301, table of contents. doi: 10.1016/j.ecl.2010.02.008. [PubMed:20511052]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Has a D-25-hydroxylase activity on both forms of vitamin D, vitamin D(2) and D(3).
- Gene Name
- CYP2R1
- Uniprot ID
- Q6VVX0
- Uniprot Name
- Vitamin D 25-hydroxylase
- Molecular Weight
- 57358.82 Da
References
- Ramos-Lopez E, Bruck P, Jansen T, Pfeilschifter JM, Radeke HH, Badenhoop K: CYP2R1-, CYP27B1- and CYP24-mRNA expression in German type 1 diabetes patients. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):807-10. Epub 2007 Jan 16. [PubMed:17223345]
- Ramos-Lopez E, Bruck P, Jansen T, Herwig J, Badenhoop K: CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev. 2007 Nov;23(8):631-6. [PubMed:17607662]
- Masuda S, Strugnell SA, Knutson JC, St-Arnaud R, Jones G: Evidence for the activation of 1alpha-hydroxyvitamin D2 by 25-hydroxyvitamin D-24-hydroxylase: delineation of pathways involving 1alpha,24-dihydroxyvitamin D2 and 1alpha,25-dihydroxyvitamin D2. Biochim Biophys Acta. 2006 Feb;1761(2):221-34. Epub 2006 Feb 2. [PubMed:16516540]
Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:17